Targets › TRIM5
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Mar 2036.
Capsid-specific restriction factor that prevents infection from non-host-adapted retroviruses. Blocks viral replication early in the life cycle, after viral entry but before reverse transcription. (UniProt, Q9C035)
Open in Phaseline: the race on TRIM5, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AIDS Malignancy Consortium | Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-pos Gene therapy using lentiviral vector expressing CCR5 shRNA, TRIM5alpha, and TAR decoy in a | CCR5, TRIM5 | Phase 1 | HIV Infection | Mar 2036 |
HIV Infection (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.